The Experimental Basis of De-Allergization Therapy11Read before the 3rd Annual Meeting of the Society for Investigative Dermatology, New York, N.Y., June 11, 1940.  by Urbach, Erich




(Received for publication June 11, 1940)
In the present state of our knowledge specific antiallergic
therapy consists of hyposensitization (desensitization) and of
de-allergization methods. On the basis of animal experiments,
it can be shown that the measures of de-allergization differ, in
principle, from those of hyposensitization. They differ with
regard to the technics employed, as well as to the fundamental
theories involved. The object of de-allergization is to convert
the organism from the existing state of high antibody titer to
one of normal antibody titer. In other words to change a
hypersensitive individual into a normal one.
It must be especially emphasized that de-allergization methods,
at least at present, can be applied only where inanimate antigens
(i.e., antigens incapable of multiplying) are concerned.
As is well known, the term hyposensitization designates the
procedures by which the organism is given small quantities of
antigen in repeated and usually increasing doses; with the result
that the blood contains an excess of free, circulating antibodies—
as demonstrable by the passive transfer test.
Under the term de-allergization, we mean all the therapeutic
measures by which antibodies actively produced by the organ-
ism, are counteracted by appropriate administration of antigen;
the antibodies are thus neutralized or otherwise rendered incap-
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able of reacting. This results first in the consumption of the
tissue-antibodies and later in the arrest of the production of
specific antibodies. In this manner, the entire organism—or
the principal shock-tissues—are rendered non-sensitive, per-
manently or for a certain length of time. Accordingly we
differentiate between a total and a partial, and between a per-
manent and a temporary de-allergization. The three following
combinations can result, and can be demonstrated by animal
experiments: (a) the partial-temporary; (b) the total-temporary;
and (c) the total-permanent state of de-allergization.
Therefore, the principal difference between the methods of
de-allergization and those of desensitization is this: when we
attempt to de-allergize, we try to neutralize the ti&sue-antibodies;
while on the other hand, when we attempt to hyposensitize, we
seek to increase the quantity of antibodies circulating in the
blood. The difference between these two most important
approaches to anti-allergic management is thus qualitative, and
not quantitative.
We employ the following methods to demonstrate the success
or the degree of the de-allergization:
(1) The Schultz-DaIe experiment, to test the specific antigen-
sensitivity of the guinea-pig uterus
(2) The lung perfusion experiment, according to Manwaring
and Kusama (2), to test the specific antigen-sensitivity
of the lung
(3) Passive transfer of the hypersensitivity by means of blood-
serum, for evidence of humoral antibodies (Prausnitz-
Küstner's technic)
In animal experiments, specific de-allergization can be achieved
in the following ways:
(a) By massive doses of specific antigen, causing severe macro-
shock
(b) By injections of specific antigen, causing slight macro-
shocks, with symptom-free state on subsequent massive
doses of antigen
(c) By means of specific skeptophylactic methods, acting














Desensitization by increasing doses
of antigen at intervals of more
than two days
DeaUergization by massive doses
of specific antigen, causing se-
vere macro-shocks
Deallergization by injection of
specific antigen causing slight
macro-shocks; symptom-free on
subsequent massive doses of an-
tigen
Deattergization by preced- I.v.
ing doses of specific an-
tigen (skeptophylaxis),
acting through micro- Orally
shocks
(A) DE-ALLERGIZATION BY MASSIVE DOSES OF SPECIFIC ANTIGENS,
CAUSING SEVERE MACRO-SHOCKS
De-allergization by means of overloading with antigens suc-
ceeds only when the proper dose of antigen has been chosen for
reinjection: that is, when the dose does bring on a severe ana-
phylactic shock, which, however, does not cause immediate death;
but is followed either by death after one to two hours, or by
ultimate survival of the animal after most severe and long-lasting
manifestations. As demonstrated by the lung perfusion experi-
ment, as well as by the Schultz-Dale test, the organs of an animal
thus exposed to long-lasting shock become de-allergized for the
lifetime of the animal: in other words no antigen-antibody reac-
tion occurs. If, on the other hand, the reinjection brings on
DE-ALLERGIZATION THERAPY 495
TABLE 1













496 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
acute, lethal anaphylactic shock, the lungs and uterus of the ani-
mal are found to be highly sensitive.
The results of these two experiments conform perfectly with
the theoretical expectations. For, in the case of lethal shock,
there is insufficient time for the tissue-antibodies to be neutralized
by the administered antigen; while, in the case of survival, the
slow neutralization brings about total and permanent, specific
non-sensitiveness of the lungs and uterus.
(B) DE-ALLERGIZATION BY INJECTIONS OF SPECIFIC ANTIGEN,
LEADING TO SLIGHT MACRO-SHOCKS, WITH SYMPTOM-FREE
STATE ON SUBSEQUENT MASSIVE DOSES OF ANTIGEN
In the course of skeptophylactic treatment (Besredka (3)),
it is possible either accidentally or intentionally that the first or
one of the later injections cause clinical, even if slight, ana-
phylactic manifestations. In such a case, the animal will be
completely refractory to a reinjection of a multiple of a lethal
dose—provided the reinjection is not given until after 4 hours
have elapsed. The basic mechanism here is different, however,
from that which results in protection from skeptophylactic
injections. For, reinjection of a lethal dose (after 4 hours) into
animals which have survived such slight macro-shocks, shows
these animals to be totally de-allergized—i.e., no antibodies can
be found in the lungs or the uterus, nor can the hypersensitivity
be transferred passively. In skeptophylactically treated guinea-
pigs, on the other hand, the uterus contains abundant antibodies
(positive Schultz-Dale test); and the hypersensitivity may be
transferred passively by way of the blood serum.
Moreover, prior to this reinjection, there is only a partial de-
allergization of the lungs, as shown by negative results in the
lung perfusion test.
We proceed now to consider the mechanism of de-allergization
by means of antigen injections eliciting distinct although slight
anaphylactic manifestations in contrast to the classic skeptophy-
lactic methods. For this we advance the following hypothesis:
Recovery from even a mild macro-shock brings about a tem-
porary satiation of the primary shock-tissues (as demonstrated
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by the negative outcome of the lung perfusion experiment). In
addition, as will be described below, this prepares for an altera-
tion in all antibody-containing tissues, so that the further ad-
ministration of antigen results, at least for a certain time, in a
state of total de-allergization. This may be demonstrated by the
absence of antibodies in the blood serum, by the absence of the
specific uterus-reaction in the Schultz-Dale experiment, and by
the negative outcome of the lung perfusion experiment.
(c) DE-ALLERGIZATION BY SPECIFIC SKEPTOPHYLACTIC METHODS,
ACTING THROUGH MICRO-SHOCKS
As is well known, the skeptophylactic method according to
Besredka (3) attains clinical non-sensitiveness (so-called anti-
anaphylaxis) by means of intravenous, intraspinal, intraperito-
neal, subcutaneous, rectal or oral administration of antigens.
Such administration should be performed in accordance with
certain indications regarding time-intervals and quantities.
It is of particular interest and also of practical importance that
the manner in which the antigen is administered (whether paren-
terally or orally) determines the mode and duration of the pro-
tection.
She ptophylactic de-allergization by the parenteral route. The
proof that the parenteral skeptophylactic methods give rise to a
de-allergization, although only partial and temporary, rather
than to a condition of temporary desensitization, is to be found
in the following animal experiments:
When an animal, previously treated by skeptophylactic
methods is again allergized, this time passively, by means of
specific antiserum, it has been shown by Weil and Coca (4) that
the same quantity of antiserum must he used as would have been
necessary to render an unprepared guinea-pig anaphylactic.
There is further proof for the concept of de-allergization,
rather than desensitization in guinea-pigs so prepared and clinic-
ally refractory to anaphylactic shock. We found, that in the
course of the lung perfusion experiment, the lungs of these aninials
did not react in any way (see figs. 1 and 2). Nevertheless, we
may speak only of partial de-allergization in the case of animals
498 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
thus prepared; for their uteri still manifested a clear-cut, specific
antigen-sensitiveness and the hypersensitivity could be passively
transferred by the blood serum.
We should like to explain this striking occurrence in the fol-
lowing manner: the principal shock-organ of the guinea-pig—-
i.e., the bronchioles and the lungs—possesses a greater avidity,
than does the uterus, for supplies of antigen, when these are
intravenously administered in less than shocking doses. It is
in the lungs, therefore, that the first antigen-antibody reaction
FIG. 1 FIG. 2
Fins. 1 AND 2. LUNG PERFUSION TEST
FIG. 1. Maximally expanded lung of a guinea-pig allergized to horse-serum,
after the introduction of the specific antigen.
FIG. 2. Partial de-allergization of a skeptophylactically treated guinea-pig
shown by the negative result of the lung perfusion test.
takes place; followed by antibody satiation, as demonstrated by
the negative outcome of the lung perfusion experiment. Under
certain conditions (see below), this partial and temporary de-
allergization can be converted into a state of total and permanent
de-allergization.
The de-allergization of shock-tissues by skeptophylactic meas-
ures can be demonstrated not only in vivo but also in vitro as
shown by Brack (5) in connection with work along otherlines.
If we add to an uterine horn of an egg white sensitized guinea-pig
a dilution of egg white of 1: 10,000 there will be an immediate
1tI' 'F
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reaction with the Schultz-Dale technic. Using the other uterine
horn, but adding the egg white in a very dilute form, e.g., 1 : 1,000-
000 and slowly increasing the concentration to 1:200, there will
be no anaphylactic reaction of the smooth muscle at all, showing
that complete antibody-satiation has taken place. Conditions
to be observed are: (a) that the horn must be suspended in each
dilution for at least 10 minutes; and (b) the Ringer's solution
must be renewed each time (see fig. 3).
When de-allergized in this manner, the uterus will preserve its
specific non-sensitiveness for the duration of its viability.
Fm. 3. DE-ALLERGIZATION IN VITRO BY SKEPTOPIIYLACTIC MEASURES
Uterus of a guinea-pig allergized to egg-white does not react in the Schultz-
Dale-test to a concentration 1:200 if previously exposed to gradually increased
doses.
Skeptophylactic de-allergization by the oral route. In numerous
experiments with a great variety of antigens we have shown as
first demonstrated by Besredka that a period of about 2 days is
necessary to achieve skeptophylactic de-allergization of the
guinea-pig with oral administration of the antigen. Further-
more, we noted the interesting finding that animals, protected
in this manner, must be considered completely de-allergized-—as
evidenced by the absence of reactions not only in their principal
shock-organ (the lung) but also in the uterus and by the failure
of passive transfer.
1
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We offer the following working hypothesis to explain how skep-
tophylactic preparation by either route succeeds in rendering
tissue-antibodies incapable of reacting, at least in the principal
shock-organs: appropriate administration of small quantities of
antigen elicits so-called micro-shocks, i.e., antigen-antibody reac-
tions—which, although clinically not perceptible, do suffice
temporarily to bind the tissue-antibodies. Newly formed
antibodies are then, in turn, satiated by antigen, either re-
peatedly administered at short intervals by the parenteral route
or by the slow absorption of antigen from the gastrointestinal
tract in the oral route. However, we should not like to consider
this glutting as a merely quantitative chemical process; but we
are of the opinion that the micro-shock goes as far as to cause an
alteration in the reactivity of the antibody-forming organs. In
other words, the micro-shock is followed not only by loss of anti-
bodies due to satiation but also by an arrest of antibody-produc-
tion, thus transforming an allergic organism into one having a
normal sensitiveness.
It is very interesting to note that skeptophylactic, intravenous
injections, performed at short intervals, bring about a state of
de-allergization which is only partial—i.e., is limited to the prin-
cipal shock organ. On the contrary, administration by mouth
with slow satiation by antigens, brings about a state of total de-
allergization. In both cases, parenteral or oral de-allergization
is, at first, oniy temporary. However, the peroral method, when
systematically followed for a period of 1 to 2 weeks, leads to a
state of permanent de-allergization, e.g., in the nutritive propeptan
treatment, in peroral hay fever treatment with seed-propeptans,
etc.
In closing, we should like to call attention to the following
noteworthy fact: namely, that under certain conditions, hypo-
sensitizing measures may also lead to de-allergization. This
may be confirmed by observations in clinical practice (achieve-
ment of a lasting non-sensitiveness by means of very long courses
of repeated hyposensitization measures (Sherman and Stull (6));
and by certain animal experiment reported by Dale (7).
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SUMMARY
The methods of de-allergization include overloading with
antigens (macro-shocks) and skeptophylaxis by preparatory
administration of minute amounts of antigens (micro-shocks).
Both depend on the consumption of ti.ssue antibodies, later leading
to the arrest of the production of specific antibodies. Because
of the consequent lack of specific antibodies, newly introduced
antigen gives rise to no antigen-antibody reaction.
The methods employing macro-shocks are not advisable be-
cause of the danger involved. Of the skeptophylactic measures
only the oral route is absolutely safe and is to be recommended
for the following reasons: in animal experiments only this technic
produces a complete satiation of the specific tissue-antibodies
and clinically yields satisfactorily permanent results as well.
The aim of hyposensitization is to cause a great increase of the
antibodies in the blood in order to bind the antigen here and to
prevent a cellular antigen-antibody reaction and therefore the
occurrence of allergic manifestation. This results however in a
strong tissue hypersensitiveness which will become apparent if
the further administration of antigen is stopped.
For these reasons methods of de-allergization would seem to
be preferable to those of hyposensitization.
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DISCUSSION
DR. MARION B. SULZBERGEB, New York City: Of course there is no doubt about
certain basic phenomena that Dr. Urbach described. For example, we know
that one can render sensitive organisms immune by exposure to their specific
allergen. Immunity can thus be acquired in several different ways.
The immunization exposure can occur either with manifest clinical reaction,
or without manifest clinical reaction. I believe this is what Dr. Urbach means
by macro and micro shock.
Obviously, in human beings it is preferable to achieve therapeutic results
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without clinical manifestations—you cannot permit a human being to have an
anaphylactoid shock as a therapeutic measure. For this reason one attempts to
produce this desensitization by doses of allergen which are incapable of producing
severe or manifest clinical reactions—that is, are incapable of eliciting
macroshock. How often, or how well one can do this varies from individual to
individual, or from allergen to allergen, and depends upon many other complex
conditions which affect the situation.
I certainly am in no disagreement with Dr. Urbach about the essential fact
that one can accomplish this desensitization and immunization in several different
ways. However, as far as human beings are concerned, the question of the rela-
tionship and role of antibodies in the mechanisms of desensitization is still almost
entirely hypothetical. We have no explanation for certain phenomena, and too
often these are glibly discussed as being due to the action or presence of anti-
bodies. Take for example, the Prausnitz-Kuestner antibody. We see many
human conditions of hypersensitivity in which there is a clinical urticarial reac-
tion when the organism is exposed to the allergen, in which no P.K. antibodies
aredemonstrable. On the other hand, many conditions obtain in human beings
in which one can demonstrate huge quantities of P.K. antibodies and yet there are
no manifestations when the individual is exposed to the allergen. In actual cases
of hay fever, particularly of treated hay fever, one very often finds phases in which
there are many antibodies, yet there is no attack precipitated when the individual
is exposed to the pollen. Then there is the question of the possible presence of
two sorts of antibodies, or of two functions of the same antibody, one having a
sensitizing effect, the other a neutralizing or desensitizing or immunizing effect.
I am sure that Dr. Urbach will agree that a good deal of study is still required
here, both in the laboratory and in man.
The last point stressed was the question of definitions. This field is still so
confused that the introduction of new concepts and new terms is likely to be dis-
advantageous rather than advantageous. Sensitive means capable of reacting.
To sensitize, therefore, means to make more capable of reacting, and to desensi-
tize means to make less capable, and.to hyposensitize means to make less capable.
It seems to me that these definitions of these words must be preserved.
Du. MILLER: I enjoyed Dr. Urbach's paper very much. Some clinical ex-
perience I had in Hungary many years ago makes me doubt however, that the
macroshock leads to desensitization or deallergization. Some twenty years ago,
dosage was not very well known, and we injected whole milk intradermally in a
patient. The patient went into allergic shock and died. Other patients who
were treated did not lose their sensitivity—they remained sen8itized. So that
the macroshock method might not only be too dangerous, but might not work.
DR. ERICH URBACH, Philadelphia: I enjoyed Dr. Sulzberger's discussion very
much. The concept of de-allergization is new in the English literature although
it was first defined in 1933. There is basic difference between the principles of
hyposensitization and of de-allergization. The methods of so-called hyposensi-
tization are those which are usually employed at present to decrease the symptoms
of hypersensitiveness in human beings and experimental animals. We claim,
however, that by this approach we further sensitize the organism if the amount
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of antibody is taken as a criterion. Of course there may be a good symptomatic
result during the course of the injections; but some weeks after treatment is
stopped the organism again manifests a high degree of sensitiveness.
I have been asked for the justification of the new term "de-allergization."
This is based on the evidence I have given that methods of de-allergization
neutralize the tissue-antibodies and alter the capacity of the antibody producing
organs. As a result the former hypersensitivity returns to a state of normal
sensitiveness.
In reply to Dr. Miller's question as to the practical application of de-allergiza-
tion, the peroral method is the only one which is recommended at present.
